

UNITED STATES PATENT AND TRADEMARK OFFICE

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

HOPEWELL PHARMA VENTURES, INC.,  
Petitioner,

v.

MERCK SERONO SA,  
Patent Owner.

---

Case IPR2023-00480  
Patent 7,713,947

---

**DECLARATION OF FRED D. LUBLIN, M.D.  
UNDER 37 C.F.R. § 1.68**

Merck 2051

## TABLE OF CONTENTS

I.	INTRODUCTION .....	1
II.	BACKGROUND AND QUALIFICATIONS .....	1
III.	SUMMARY OF OPINIONS .....	6
IV.	LEVEL OF SKILL IN THE ART .....	11
V.	LEGAL STANDARDS .....	12
	A.    OBVIOUSNESS .....	12
	B.    CLAIM CONSTRUCTION .....	14
VI.	TECHNICAL FIELD OF THE ART .....	14
	A.    Multiple Sclerosis.....	14
	1.    MS Clinical Course and Diagnosis.....	15
	2.    MS Treatment as of 2004.....	18
	3.    Outcome Measures In MS Clinical Trials .....	24
	4.    Cladribine Investigations For MS.....	26
	B.    Alleged Prior Art.....	31
	1.    Bodor (Ex. 1022).....	31
	2.    Stelmasiak (Ex. 1013).....	32
VII.	THE '947 PATENT INVENTION.....	34
VIII.	THE CHALLENGED CLAIMS WOULD NOT HAVE BEEN OBVIOUS OVER BODOR AND STELMASIAK .....	37
	A.    Neither Bodor Nor Stelmasiak Discloses Or Suggests All Limitations Of The Challenged Claims .....	38
	1.    Neither Bodor Nor Stelmasiak Discloses Or Suggests The Claimed Weight-Based Induction Or Maintenance Dosing .....	38

2. Neither Bodor Nor Stelmasiak Discloses Or Suggests A Maintenance Period As Claimed .....44

a. Bodor Does Not Teach or Suggest Re-Treatment.....44

    i. Cladribine Treatment Raises Safety Concerns.....45

    ii. Dosing of Approved Disease-Modifying Treatments For MS Was Based on Pharmacological Effects, Efficacy, And Safety.....47

    iii. The Art Did Not Suggest A Maintenance Period As Claimed .....53

b. Stelmasiak Does Not Teach Or Suggest A Maintenance Period As Claimed.....57

c. A POSA Would Not Have Arrived At The Claimed Maintenance Period Based on Routine Optimization .....59

B. A POSA Would Not Have Been Motivated To Combine Bodor With Stelmasiak To Arrive At The Challenged Claims With A Reasonable Expectation Of Success .....64

    1. A POSA Would Not Have Been Motivated To Arrive At The Claimed Dosing Methods Via Routine Optimization Or Have Had A Reasonable Expectation Of Success In Doing So .....65

2. A POSA Would Not Have Been Motivated To Adopt Weight-Based Dosing Or Have Reasonably Expected To Arrive At The Claimed Weight-Based Dosing Regimen .....86

3. A POSA Would Not Have Been Motivated To Combine Bodor With Stelmasiak To Arrive At The Claimed Induction Doses Or Have Had A Reasonable Expectation Of Success In Doing So .....87

4. A POSA Would Not Have Been Motivated To Immediately Re-Treat Patients After Bodor’s 10-Month Cladribine-Free Period Or Have Had A Reasonable Expectation Of Success In Doing So .....94

5. A POSA Would Not Have Been Motivated To Combine Bodor With Stelmasiak To Arrive At The Claimed 1.7 Mg/Kg Maintenance Dose Or Have Had A Reasonable Expectation Of Success In Doing So .....98

C. The Dependent Claims Would Not Have Been Obvious Over Bodor And Stelmasiak .....101

IX. OBJECTIVE INDICIA SUPPORT THE NON-OBVIOUSNESS OF THE CHALLENGED CLAIMS OF THE ’947 PATENT.....103

A. Skepticism Of Others .....103

B. Unexpected Results .....107

C. Long-Felt Need.....113

D. Nexus.....116

X. CONCLUSION.....135

I, Fred D. Lublin, M.D., declare as follows:

## **I. INTRODUCTION**

1. I am over eighteen years of age, and I am competent to testify as to the matters set forth herein if I am called upon to do so.

2. I have prepared this Declaration for consideration by the Patent Trial and Appeal Board in the following *Inter Partes* Review proceeding: IPR2023-00480. I understand that IPR2023-00480 corresponds to *Inter Partes* Review of U.S. Patent No. 7,713,947 (the “947 patent”) (Ex. 1001).

3. I have written this Declaration on behalf of Merck Serono SA in connection with the above-captioned *Inter Partes* Review proceeding. I am being compensated for my time at my normal consulting rate of \$900 per hour for non-deposition time and a \$9,000 flat fee per day for deposition time. My compensation is not dependent on the substance of my testimony or the outcome of the proceedings.

4. In forming my opinions, in addition to my knowledge and experience, I have considered the materials cited herein and listed in Appendix A.

5. All statements in my Declaration, unless indicated otherwise, are based on my knowledge and experience in the field.

## **II. BACKGROUND AND QUALIFICATIONS**

6. I am a Professor of Neurology and the Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at the Icahn School of

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.